Skip to content

Savara SVRA Free cash flow yield

Free cash flow yield at other companies

Innoviva, Inc. logo
Innoviva, Inc.INVA
17.6%+1.8pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-9.3%-3.7pp
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
11.1%+6.5pp
Theravance Biopharma logo
Theravance BiopharmaTBPH
25.2%+23.0pp
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
6.1%
TRV
Trevi Therapeutics, Inc.TRVI
-23.9%

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+236%
Enterprise value$1.19B+224%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Calculated from Savara’s reported figures.

Based on trailing twelve months.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's free cash flow yield?
Savara (SVRA) reported free cash flow yield of -9.6% in Q1 2026.
How has Savara's free cash flow yield changed year-over-year?
Savara's free cash flow yield increased by 52.1% year-over-year, from -20% to -9.6%.
What is the long-term trend for Savara's free cash flow yield?
Over 3 years (2020 to 2025), Savara's free cash flow yield has grown at a -43.2% compound annual growth rate (CAGR), from -45% to -8.2%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.